Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Breast Cancer Research and Treatment
Erschienen in: Breast Cancer Research and Treatment 1/2011

01.08.2011 | Preclinical study

BRCA1 promoter methylation in peripheral blood cells is associated with increased risk of breast cancer with BRCA1 promoter methylation

verfasst von: Takashi Iwamoto, Noriaki Yamamoto, Tetsuya Taguchi, Yasuhiro Tamaki, Shinzaburo Noguchi

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

BRCA1 promoter methylation reportedly plays an important part in the pathogenesis of human breast cancer. In the present study, we investigated whether or not BRCA1 promoter methylation in peripheral blood cells (PBCs) can serve as a risk factor for developing breast cancer. The association of BRCA1 promoter methylation in PBCs with breast cancer risk was examined in a case–control study (200 breast cancer patients and 200 controls). BRCA1 promoter methylation in PBCs and breast tumors was determined with a methylation-specific quantitative PCR assay. BRCA1 promoter methylation in PBCs was seen in 43 (21.5%) of the breast cancer patients and in 27 (13.5%) of the controls. The odds ratio for breast cancer adjusted for other epidemiological risk factors was 1.73 (1.01–2.96) and was statistically significant (P = 0.045). When breast tumors were classified into those with and without BRCA1 promoter methylation, the odds ratio was 0.84 (0.43–1.64) (P = 0.61) for BRCA1 promoter methylation-negative and 17.78 (6.71–47.13) (P < 0.001) for BRCA1 promoter methylation-positive breast tumors. BRCA1 promoter methylation in PBCs is significantly associated with risk of breast cancer with BRCA1 promoter methylation. This seems to indicate that BRCA1 promoter methylation in PBCs may constitute a novel risk factor for breast cancer with BRCA1 promoter methylation.
Literatur
1.
Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266(5182):66–71PubMedCrossRef
2.
Easton DF, Bishop DT, Ford D et al (1993) Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 52(4):678–701PubMed
3.
Ford D, Easton DF, Bishop DT et al (1994) Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343(8899):692–695PubMedCrossRef
4.
Merajver SD, Frank TS, Xu J et al (1995) Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer. Clin Cancer Res 1(5):539–544PubMed
5.
Cornelis RS, Neuhausen SL, Johansson O et al (1995) High allele loss rates at 17q12-q21 in breast and ovarian tumors from BRCAl-linked families. The Breast Cancer Linkage Consortium. Genes Chromosom Cancer 13(3):203–210PubMedCrossRef
6.
Takano M, Aida H, Tsuneki I et al (1997) Mutational analysis of BRCA1 gene in ovarian and breast-ovarian cancer families in Japan. Jpn J Cancer Res 88(4):407–413PubMed
7.
Zhang J, Powell SN et al (2005) The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Mol Cancer Res 3(10):531–539PubMedCrossRef
8.
Ting NS, Lee WH et al (2004) The DNA double-strand break response pathway: becoming more BRCAish than ever. DNA Repair (Amst) 3(8–9):935–944CrossRef
9.
Yoshida K, Miki Y et al (2004) Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci 95(11):866–871PubMedCrossRef
10.
Mullan PB, Quinn JE, Harkin DP et al (2006) The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene 25(43):5854–5863PubMedCrossRef
11.
Somasundaram K et al (2003) Breast cancer gene 1 (BRCA1): role in cell cycle regulation and DNA repair–perhaps through transcription. J Cell Biochem 88(6):1084–1091PubMedCrossRef
12.
Xia Y, Pao GM, Chen HW et al (2003) Enhancement of BRCA1 E3 ubiquitin ligase activity through direct interaction with the BARD1 protein. J Biol Chem 278(7):5255–5263PubMedCrossRef
13.
Hashizume R, Fukuda M, Maeda I et al (2001) The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem 276(18):14537–14540PubMedCrossRef
14.
Futreal PA, Liu Q, Shattuck-Eidens D et al (1994) BRCA1 mutations in primary breast and ovarian carcinomas. Science 266(5182):120–122PubMedCrossRef
15.
Xu CF, Solomon E et al (1996) Mutations of the BRCA1 gene in human cancer. Semin Cancer Biol 7(1):33–40PubMedCrossRef
16.
Yang Q, Yoshimura G, Nakamura M et al (2002) BRCA1 in non-inherited breast carcinomas (Review). Oncol Rep 9(6):1329–1333PubMed
17.
Matros E, Wang ZC, Lodeiro G et al (2005) BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat 91(2):179–186PubMedCrossRef
18.
Wei M, Grushko TA, Dignam J et al (2005) BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res 65(23):10692–10699PubMedCrossRef
19.
Birgisdottir V, Stefansson OA, Bodvarsdottir SK et al (2006) Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res 8(4):R38PubMedCrossRef
20.
Catteau A, Morris JR et al (2002) BRCA1 methylation: a significant role in tumour development? Semin Cancer Biol 12(5):359–371PubMedCrossRef
21.
Catteau A, Harris WH, Xu CF et al (1999) Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 18(11):1957–1965PubMedCrossRef
22.
Bianco T, Chenevix-Trench G, Walsh DC et al (2000) Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer. Carcinogenesis 21(2):147–151PubMedCrossRef
23.
Tapia T, Smalley SV, Kohen P et al (2008) Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors. Epigenetics 3(3):157–163PubMedCrossRef
24.
Miyoshi Y, Murase K, Oh K et al (2008) Basal-like subtype and BRCA1 dysfunction in breast cancers. Int J Clin Oncol 13(5):395–400PubMedCrossRef
25.
Snell C, Krypuy M, Wong EM et al (2008) RCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype. Breast Cancer Res 10(1):R12PubMedCrossRef
26.
Flanagan JM, Munoz-Alegre M, Henderson S et al (2009) Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients. Hum Mol Genet 18(7):1332–1342PubMedCrossRef
27.
Arai T, Miyoshi Y, Kim SJ et al (2006) Association of GSTP1 CpG islands hypermethylation with poor prognosis in human breast cancers. Breast Cancer Res Treat 100(2):169–176PubMedCrossRef
28.
Hasegawa S, Miyoshi Y, Egawa C et al (2002) Mutational analysis of the class I beta-tubulin gene in human breast cancer. Int J Cancer 101(1):46–51PubMedCrossRef
29.
Miyoshi Y, Ando A, Hasegawa S et al (2003) Association of genetic polymorphisms in CYP19 and CYP1A1 with the oestrogen receptor-positive breast cancer risk. Eur J Cancer 39(17):2531–2537PubMedCrossRef
30.
Fackler MJ, Malone K, Zhang Z et al (2006) Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin Cancer Res 12(11 Pt 1):3306–3310PubMedCrossRef
31.
Tsuda H, Sasano H, Akiyama F et al (2002) Evaluation of interobserver agreement in scoring immunohistochemical results of HER-2/neu (c-erbB-2) expression detected by HercepTest, Nichirei polyclonal antibody, CB11 and TAB 250 in breast carcinoma. Pathol Int 52(2):126–134PubMedCrossRef
32.
Shibuta K, Ueo H, Furusawa H et al (2010) The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer. Breast Cancer. doi:10.​1007/​s12282-010-0209-6
33.
Cristofanilli M, Budd GT, Ellis MJ et al (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351(8):781–791PubMedCrossRef
34.
Niwa Y, Oyama T, Nakajima T et al (2000) BRCA1 expression status in relation to DNA methylation of the BRCA1 promoter region in sporadic breast cancers. Jpn J Cancer Res 91(5):519–526PubMed
35.
Miyamoto K, Fukutomi T, Asada K et al (2002) Promoter hypermethylation and post-transcriptional mechanisms for reduced BRCA1 immunoreactivity in sporadic human breast cancers. Jpn J Clin Oncol 32(3):79–84PubMedCrossRef
36.
Mirza S, Sharma G, Prasad CP et al (2007) Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. Life Sci 81(4):280–287PubMedCrossRef
37.
Chen Y, Toland AE, McLennan J et al (2006) Lack of germ-line promoter methylation in BRCA1-negative families with familial breast cancer. Genet Test 10(4):281–284PubMedCrossRef
38.
Issa JP, Ottaviano YL, Celano P et al (1994) Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 7(4):536–540PubMedCrossRef
39.
Suijkerbuijk KP, Fackler MJ, Sukumar S et al (2008) Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer. Ann Oncol 19(11):1870–1874PubMedCrossRef
40.
Gonzalo S et al (2009) Epigenetic alterations in aging. J Appl Physiol 109(2):589–597
41.
Kontorovich T, Cohen Y, Nir U et al (2009) Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and P53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers. Breast Cancer Res Treat 116(1):195–200PubMedCrossRef
42.
Chan TL, Yuen ST, Kong CK et al (2006) Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer. Nat Genet 38(10):1178–1183PubMedCrossRef
43.
Galizia E, Giorgetti G, Piccinini G et al (2010) BRCA1 expression in triple negative sporadic breast cancers. Anal Quant Cytol Histol 32(1):24–29PubMed
44.
Lee JS, Fackler MJ, Lee JH et al. (2010) Basal-like breast cancer displays distinct patterns of promoter methylation. Cancer Biol Ther 9(12):1017–1024
45.
Smith RE, Good BC et al (2003) Chemoprevention of breast cancer and the trials of the National Surgical Adjuvant Breast and Bowel Project and others. Endocr Relat Cancer 10(3):347–357PubMedCrossRef
46.
Visvanathan K, Chlebowski RT, Hurley P et al (2009) American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27(19):3235–3258PubMedCrossRef
47.
Rottenberg S, Jaspers JE, Kersbergen A et al (2008) High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 105(44):17079–17084PubMedCrossRef
48.
Fong PC, Boss DS, Yap TA et al (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2):123–134PubMedCrossRef
49.
Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752PubMedCrossRef
50.
Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100(14):8418–8423PubMedCrossRef
51.
Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21):2492–2502PubMedCrossRef
Metadaten
Titel
BRCA1 promoter methylation in peripheral blood cells is associated with increased risk of breast cancer with BRCA1 promoter methylation
verfasst von
Takashi Iwamoto
Noriaki Yamamoto
Tetsuya Taguchi
Yasuhiro Tamaki
Shinzaburo Noguchi
Publikationsdatum
01.08.2011
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2011
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-1188-1

Weitere Artikel der Ausgabe 1/2011

Breast Cancer Research and Treatment 1/2011 Zur Ausgabe

Letter to the Editor

XPC gene polymorphisms and breast cancer susceptibility: appraisal of a recent meta-analysis

Epidemiology

PD-1 polymorphisms are associated with sporadic breast cancer in Chinese Han population of Northeast China

Brief Report

Clinical significance of circulating tumor cells in breast cancer patients

Preclinical study

High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions

Clinical trial

Clinical application of shear wave elastography (SWE) in the diagnosis of benign and malignant breast diseases

Epidemiology

Long-term quality of life after breast cancer: a French registry-based controlled study

Neu im Fachgebiet Onkologie

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise